Britain’s Biggest Private Hospital Chain

Britain’s Biggest Private Hospital Chain

Satirical Illustration

Hedge Fund Buys Britain’s Biggest Private Hospital Chain for £1bn: At Last, Healthcare With a Proper Invoice

The Rottweiler did not create the bargain, he simply priced it

LONDON — Spire Healthcare, the country’s largest private hospital group, has agreed a £1.03 billion takeover by a consortium led by Toscafund, the vehicle of Martin Hughes, a City operator nicknamed “the Rottweiler.” Shareholders get 250p a share, a 66 per cent premium to the undisturbed May price. Thirty-eight hospitals, more than fifty clinics, 1.36 million patients last year, and now a hedge fund with a flower-themed bid company called Tulip. Britain’s two-tier health service has found its florist.

  • Investors diagnosed Spire Healthcare with undervalued equity and produced a £1.03 billion treatment plan without requiring a GP referral.
  • Britain’s largest private hospital operator will now have a hedge fund in the waiting room, quietly asking whether every patient really needs both kidneys.
  • Toscafund’s Martin Hughes is nicknamed “the Rottweiler,” making this the first hospital takeover in which the watchdog purchased the hospital.
  • The agreement followed repeated takeover-deadline extensions, allowing investors to experience an authentic British healthcare waiting-list journey.
  • Patients will continue being called patients, although somewhere inside the finance department they have already been renamed “recurring organic demand.”

Spire Healthcare takeover Toscafund: an on-the-nose revolving door

Toscafund was already the second-largest shareholder. THCP and Ares complete the consortium. Chief executive Justin Ash steps down. Sir David Sloman, once NHS England’s chief operating officer, becomes interim CEO, a detail so on-the-nose a satirist would have rejected it as implausible. The man who helped run the public service will now warm the seat for private owners. Paolo Pieri, formerly of Circle Health, is lined up as chair after completion. The revolving door has been clinically cleaned and left ajar.

The board says the sector is volatile and cost pressures are “material,” including national insurance and the minimum wage. Translation: looking after people got more expensive, so the people who look after the shareholders have accepted a cheque. Debbie White, chair-designate, called it the best available outcome for investors. Patients were not in the sentence. They rarely are at 250p.

Not the NHS being sold, the other one

This is not the NHS being sold. It is the parallel system that already treats the insured, the self-pay, and the overflow the NHS cannot absorb, moving from a listed company into funds that like cashflow and dislike sentiment. Private hospitals are not a scandal in themselves. A country with waiting lists will use them. The scandal is the pretence that ownership is a technicality. Funds extract. That is the job. When the asset is an operating theatre, extraction still looks like a dividend.

As one City analyst reportedly quipped over the deal terms, “You can tell it’s a healthcare acquisition because everyone involved keeps calling the profit margin ‘patient outcomes’ with a straight face.” Nobody on the call laughed. That, apparently, was the point.

Same owner temperature, different postcode

Critics will shout privatisation. Supporters will shout efficiency. Both will be half right. Spire already was private. What changes is the temperature of the owner. A FTSE 250 company has reports, analysts, and a public share price that can be embarrassed. A consortium can be quieter, more leveraged, and more certain that a knee replacement is a return profile.

Hughes’s nickname will do a lot of tabloid work. Ignore the dog. Watch the enterprise value: about £2.3 billion including debt. Watch the NHS waiting list, which is the silent joint-venture partner in every private hospital deal. When the state cannot offer a date, the market offers a price. The Rottweiler did not create that bargain. He merely priced it.

One project glows, the other invoices

If you want a closing image for this news cycle, pair the Yorkshire glowworm with the Tulip bidco. One project cost almost nothing and produced light. The other costs a billion and produces a scheme of arrangement. Both are, in their way, British. Only one of them glows in the dark without sending an invoice.

The strategic review that took a year to find its own second-largest shareholder

Spare a thought for the process itself. Spire’s board ran a strategic review for the best part of a year, advised by Rothschild, and spoke to more than sixty potential buyers before landing on the party that already sat on its own share register. Bridgepoint and Triton both circled and walked away in March. A company can spend twelve months searching the world for a saviour and still end up marrying the neighbour it had been quietly dating the whole time. When the approach became public, Spire’s shares jumped 38 per cent in a single session, which tells you rather more about where the market thought the stock had been sitting than it does about any sudden burst of hospital efficiency.

Going private is being sold as liberation from quarterly reporting, freedom to invest in theatres and digital systems without justifying every pound to institutional shareholders. That may even be true. It is also, conveniently, freedom from having to explain the numbers to anyone outside the consortium at all.

Investors diagnosed Spire Healthcare with undervalued equity and produced a £1.03 billion treatment plan without requiring a GP referral. Britain’s largest private hospital operator now has a hedge fund in the waiting room, quietly asking whether every patient really needs both kidneys. Toscafund’s Martin Hughes is nicknamed “the Rottweiler,” which makes this, technically, the first hospital takeover in which the watchdog bought the hospital. The deal followed repeated deadline extensions, giving the investors a small taste of an authentic British healthcare waiting-list experience before they had even signed anything. Patients, for now, will keep being called patients, though somewhere inside the finance department they have almost certainly already been renamed “recurring organic demand.”

Sources

Spire agreed a 250p-a-share cash offer from Tulip UK Bidco, a consortium of Toscafund, THCP Advisory and Ares, valuing the company’s equity at about £1.03 billion, a 66 per cent premium to its price before takeover talks became public. Spire runs 38 hospitals and around 55 clinics. Chief executive Justin Ash and chairman Sir Ian Cheshire are both departing, with Sir David Sloman stepping in as interim chief executive and Debbie White as interim chair. Concerns persist about the growing role of private capital alongside the NHS.

This is British satire, filed in the tradition of UK satirical journalism that has always kept one eye on the balance sheet whenever the health service comes up. British satirical news rarely runs short of material where hospitals and hedge funds share a sentence.

For more satirical coverage from the other side of the pond, visit Bohiney.com.

Auf Wiedersehen, amigo!

Leave a Reply

Your email address will not be published. Required fields are marked *